Leading Pediatric Eye Care Brand Future Vision Completes Series B Funding Round

VCBeat (WeChat: vcbeat) learned第一时间 that Runer Health, a leading brand in pediatric ophthalmology,Runer HealthAnnouncement CompletedSeries BFinancing. This round of financing was led byYuanBio Venture CapitalLed the investment, old shareholdersChengshu InvestmentCo-investment,Probe CapitalAct as the exclusive financial advisor.

Runer Health was founded in 2015, with its headquarters located in Lujiazui, Pudong, Shanghai.Runer Health is an eye health chain service brand that integrates ophthalmic clinic chains with the research, development, and sales of eye care products.. Having in Shanghai12 Ophthalmic Chain Institutions, providing standardized diagnosis and treatment services with advanced technology and equipment, has a professional team of ophthalmologists, optometrists, and nurses. The scope of services includes comprehensive eye examinations, prevention and treatment of eye diseases, medical optometry and eyeglass fitting, vision training, etc., focusing on myopia prevention and control for teenagers and children, correction of refractive errors (myopia, hyperopia, astigmatism), amblyopia training, pre- and post-operative binocular vision function training for strabismus, adult medical optometry and eyeglass fitting, and basic eye disease treatment services such as dry eye.

For this round of financingNotRuner Health Founding TeamRuner Health stated: "Runer Health is committed to becoming the most trusted pediatric ophthalmology chain brand in China, providing customers with professional, safe, and effective full life cycle eye health solutions. We always adhere to our corporate culture of 'Customer First, Adaptability, Teamwork and Trust, and the Spirit of Champions,' leading our entrepreneurial team to continuously move forward, engage in lifelong learning, and rapidly iterate. Currently, the pediatric ophthalmology clinic sector remains a blue ocean market. Runer Health will seize this opportunity, establish a strong presence in Shanghai, expand steadily across the Yangtze River Delta region, serve more customers, and provide the greatest returns to our customers, shareholders, and employees."

Mr. Liu Xiao, Executive Director of YuanBio Venture CapitalStated: "Ophthalmology is an important track that we continue to focus on. It is an honor that YuanBio Venture Capital led the B-round investment in Runer Health. The founding team has extremely high business acumen, and the core team is united and strong. After several years of entrepreneurial exploration, they have found a replicable business model. We believe that the current issue of juvenile myopia has gained significant societal attention, and notable changes in purchasing behavior on the demand side have provided Runer Health with an excellent opportunity for rapid development. We look forward to the company expanding its offline business across cities, further strengthening its online e-commerce and 2B sales capabilities, and developing more home-use ophthalmic prevention and control devices. We hope that, with the support of YuanBio, Runer Health will become a well-known brand in juvenile myopia prevention and control."

Wu Yinghui, Partner of Chengshu InvestmentMr.Expressed: "We are very pleased to continue participating in the new round of financing for Runer Health. Ophthalmic medical care is a细分赛道 that Chengshu Investment has long been optimistic about and focused on. The pediatric optometry market is still in its early stages, with a potential worth billions, and holds immense future promise. As the largest pediatric ophthalmology chain institution in Shanghai, Runer Health has established more than ten ophthalmology clinics and optometry centers in the Shanghai area, boasting high customer satisfaction and strong user loyalty. The company's team has rich operational management experience, strong execution capabilities, and a deep understanding of user needs. We look forward to Runer Health continuing to provide users with professional and comfortable eye health products and services, becoming a leading brand in one-stop solutions for myopia prevention and control among Chinese youth."

Mr. Cheng Xiangkuan, Managing Director of Probe Capital"It is a great honor to serve as the exclusive financial advisor for Runer Health's Series B financing round. The ophthalmology sector has always been a golden track in China, and pediatric ophthalmology is the most explosive among all sub-tracks. As a chain service provider that integrates online and offline closed-loop pediatric ophthalmology services, Runer Health offers users a one-stop, full lifecycle management solution for children’s vision care, covering services, products, and content. Currently, Runer Health is the largest pediatric ophthalmology chain institution in East China, and we look forward to Runer Health becoming the leading brand in China's pediatric ophthalmology field."

YuanBio Venture Capital is an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou bioBAY with a global reach. To date, it has successfully invested in over 140 outstanding companies in the life sciences and health industry, spanning four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services, achieving substantial investment returns. Among these, 14 companies have been listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has repeatedly been recognized as one of the Top 10 venture capital funds in China's healthcare sector and one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, YuanBio Venture Capital possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging its professionalism, focus, and rich industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Founded in 2010, Chengshu Investment focuses on growth-stage investments in the healthcare sector, with particular attention to growth-stage and early-stage investment opportunities in consumer healthcare and life sciences. The Chengshu management team has a deep understanding of business growth patterns, possesses extensive industry resources and capital market experience, and is committed to continuously empowering the growth of portfolio companies and creating long-term sustainable value for investors.

Probe Capital was founded in 2017 as a boutique investment bank specializing in healthcare and life sciences. Its businesses include financial advisory, direct investment, industry consulting, and innovation incubation. The founding team comes from top-tier private equity investment firms, financial advisory institutions, management consulting companies, and vertical medical media in the industry. Since its establishment, Probe Capital has completed double-digit private financings and M&A transactions annually, with a cumulative transaction value exceeding tens of billions of RMB. In terms of value-added services for enterprises, the Probe Capital team also possesses mature industry experience. In 2020, Probe New Medical Fund was established and has since invested in more than ten leading companies in the industry.